0001628280-26-054746 | 10-Q | XBRL Viewer

Print Document

Goodwill and Other Intangible Assets (Schedule of Gross Carrying Values, Accumulated Amortization, and Approximate Amortization Period of Definite Lived Intangible Assets) (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Intangible Asset, Finite-Lived [Line Items]
Net Carrying Value	$ 149,274	$ 123,664
Other intangibles, net
Intangible Asset, Finite-Lived [Line Items]
Gross Carrying Value	51,819	52,063
Accumulated Amortization	20,257	23,536
Net Carrying Value	$ 31,562	$ 28,527
Weighted Average Useful Life (Years)	9 years	9 years 9 months 18 days
Acquired technology
Intangible Asset, Finite-Lived [Line Items]
Gross Carrying Value	$ 238,195	$ 208,235
Accumulated Amortization	88,921	84,571
Net Carrying Value	$ 149,274	$ 123,664
Weighted Average Useful Life (Years)	16 years 4 months 24 days	18 years 1 month 6 days
Customer lists and relationships
Intangible Asset, Finite-Lived [Line Items]
Gross Carrying Value	$ 28,790	$ 28,853
Accumulated Amortization	13,693	13,057
Net Carrying Value	$ 15,097	$ 15,796
Weighted Average Useful Life (Years)	21 years 7 months 6 days	21 years 6 months
Patents
Intangible Asset, Finite-Lived [Line Items]
Gross Carrying Value	$ 1,322	$ 4,658
Accumulated Amortization	255	3,523
Net Carrying Value	$ 1,067	$ 1,135
Weighted Average Useful Life (Years)	17 years	17 years
Other
Intangible Asset, Finite-Lived [Line Items]
Gross Carrying Value	$ 21,707	$ 18,552
Accumulated Amortization	6,309	6,956
Net Carrying Value	$ 15,398	$ 11,596
Weighted Average Useful Life (Years)	5 years	5 years

Acquisition of Ascyrus

6 Months Ended

Jun. 30, 2026

Business Combination [Abstract]

Acquisition of Ascyrus

Overview

On September 2, 2020 we entered into a Securities Purchase Agreement (the “Ascyrus Agreement”) to acquire 100% of the outstanding equity interests of Ascyrus Medical LLC (“Ascyrus”). Ascyrus developed the AMDS, the world’s first aortic arch remodeling device for use in the treatment of acute Type A aortic dissections.

Under the terms of the Ascyrus Agreement, we will pay an aggregate of up to $200.0 million in consideration, consisting of: (i) a cash payment of approximately $60.0 million and the issuance of $20.0 million in shares of Artivion common stock, in each case, that were delivered at the closing of the acquisition, (ii) a cash payment of $10.0 million and the issuance of $10.0 million in shares of Artivion common stock upon FDA approval of the Investigational Device Exemption (“IDE”) application for the AMDS in 2021, (iii) if the FDA approves PMA application submitted for the AMDS, a cash payment of $25.0 million, (iv) if regulatory approval of the AMDS is obtained in Japan on or before June 30, 2027, a cash payment of $10.0 million, (v) if regulatory approval of the AMDS is obtained in China on or before June 30, 2027, a cash payment of $10.0 million and (vi) a potential additional consideration cash payment capped at $55.0 million (or up to $65.0 million to $75.0 million if the Japanese or Chinese approvals are not secured on or before June 30, 2027 and those approval milestone payments are added to the potential additional consideration cash payment cap) calculated as two times the incremental worldwide sales of the AMDS (or any other acquired technology or derivatives of such acquired technology) outside of the European Union during the three-year period following the date the FDA approves a PMA application submitted for the AMDS.

Accounting for the Transaction

In June 2026 the FDA approved the PMA application for the AMDS Hybrid Prosthesis for use in patients with acute DeBakey Type I aortic dissections with clinical or radiographic malperfusion, satisfying the related regulatory milestone and triggering the associated $25.0 million contingent payment, which was paid in July 2026.

As part of the acquisition, we may be required to pay additional consideration up to $100.0 million to the former shareholders of Ascyrus upon the achievement of certain milestones and the sales-based additional earnout described above.

The contingent consideration represents the estimated fair value of future potential payments. The fair value of the contingent consideration liability was estimated by discounting to present value the contingent payments expected to be made based on a probability-weighted scenario approach. We applied a discount rate based on our unsecured credit spread and the term commensurate risk-free rate to the additional consideration to be paid, and then applied a risk-based estimate of the probability of achieving each scenario to calculate the fair value of the contingent consideration. This fair value measurement was based on unobservable inputs, including management estimates and assumptions about the future achievement of milestones and future estimate of revenues, and is, therefore, classified as Level 3 within the fair value hierarchy. We used a discount rate of approximately 16% and estimated future achievement of milestone dates to calculate the fair value of contingent consideration as of June 30, 2026. We remeasure this liability at each reporting date and record changes in the fair value of the contingent consideration in General, administrative, and marketing expenses in the Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income. Increases or decreases in the fair value of the contingent consideration liability can result from changes in the passage of time, discount rates, the timing and amount of our revenue estimates, and the timing and expectation of regulatory approvals.

We perform quarterly assessments of the fair value of our contingent consideration liabilities. We recorded net fair value losses of $8.0 million and $9.7 million for the three and six months ended June 30, 2026, respectively, compared with a net fair value loss of $2.6 million and a net fair value gain of $0.2 million for the three and six months ended June 30, 2025, respectively. These amounts were recognized in General, administrative, and marketing expenses in the Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income. The $9.7 million increase in the fair value of the contingent consideration liabilities during the six months ended June 30, 2026 was primarily attributable to the increase in the probability of achieving the PMA approval milestone to 100% upon receipt of FDA approval as described above, the passage of time, and a slightly lower credit spread.

As of June 30, 2026 the contingent consideration liabilities related to AMDS totaled $70.3 million, of which $25.0 million was classified in current portion of contingent consideration and related to the PMA approval milestone achieved in June 2026. As of December 31, 2025 the contingent consideration liabilities totaled $60.6 million.

Acquisition of Endospan

Overview

On May 18, 2026 (the “Acquisition Date”), we acquired 100% of the outstanding securities of Endospan Ltd. (“Endospan”) from its securityholders (the “Endospan Acquisition”). The Endospan Acquisition was completed through the exercise of our purchase option pursuant to the Securities Purchase Option Agreement, dated September 11, 2019, as amended on July 1, 2024 and January 9, 2026 (the “Agreement”). Endospan designs, develops, manufactures, and commercializes the NEXUS™ family of aortic arch stent graft systems. The Endospan Acquisition expands our aortic arch product portfolio and provides us with ownership of the NEXUS platform and related product-development pipeline.

We accounted for the Endospan Acquisition as a business combination using the acquisition method of accounting in accordance with ASC 805, Business Combinations. The Agreement provided for a base purchase price of $175.0 million, payable in cash and subject to adjustments for working capital, indebtedness, cash, transaction expenses, and other specified items. The acquisition-date fair value of total consideration transferred was $178.1 million, as summarized below. At closing, we paid approximately $131.3 million in cash in connection with the Endospan Acquisition. This amount included $10.2 million of transaction bonuses, as further discussed below. The remaining $121.0 million consisted of $106.8 million of cash consideration and $14.2 million paid to settle Endospan debt obligations.

Endospan’s former securityholders are also entitled to receive contingent consideration of up to $200.0 million based on 2.5 times the increase in worldwide revenue from sales of NEXUS™ products during the 12-month period ending on the second anniversary of the Acquisition Date compared with the 12-month period preceding the Acquisition Date. Any amount payable will be determined following the second anniversary of the Acquisition Date and paid in accordance with the Agreement. The contingent consideration had an acquisition-date fair value of $26.2 million and remained materially unchanged as of June 30, 2026. The liability was included in Non-current contingent consideration in the Condensed Consolidated Balance Sheets. See Note 5 – “Financial Instruments” for additional information regarding the valuation of the contingent consideration.

We incurred acquisition-related costs of $11.7 million and $12.5 million during the three and six months ended June 30, 2026, respectively, including $10.2 million of transaction bonuses recognized in connection with the Endospan Acquisition. These costs were accounted for separately from the business combination, expensed as incurred, and included in General, administrative, and marketing expenses in the Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income.

We recorded preliminary goodwill of $99.2 million, of which none is expected to be deductible for income tax purposes. Goodwill represents the excess of the consideration transferred over the fair value of the identifiable net assets acquired and primarily reflects expected synergies from the Endospan Acquisition and the value of the assembled workforce. The entire balance of acquired goodwill was assigned to our Medical Devices segment. The preliminary purchase price allocation is based on information available as of June 30, 2026 and remains subject to adjustment, primarily related to the finalization of working capital and other closing adjustments and income tax matters. The measurement period will not exceed one year from the Acquisition Date, as additional information about facts and circumstances existing at the Acquisition Date becomes available. Measurement-period adjustments will be recognized as if the accounting had been completed at the Acquisition Date, including the related effect on depreciation, amortization, and other income-statement amounts.

The preliminary purchase consideration allocated as of the Acquisition Date consisted of the following (in thousands):


Consideration
Cash consideration	$	106,818
Debt obligations settled in cash by Artivion	14,206
Noncash settlement of preexisting relationships and Endospan Option (1)	30,811
Contingent consideration	26,227
Fair value of total consideration transferred	$	178,062

Purchase Price Allocation
Cash and cash equivalents	$	4,363
Intangible assets, net	71,800
Net other assets/liabilities acquired	2,693
Goodwill	99,206
Net assets acquired	$	178,062

(1) Represents amounts included in consideration transferred in connection with the settlement or exercise of preexisting contractual relationships between Artivion and Endospan, consisting of the acquisition-date fair value of the effective settlement of the Endospan Loans ($24.7 million) and the Buyer Deposits ($3.0 million), and the carrying amount of the Endospan Option ($3.1 million) upon exercise. See “Settlement of Preexisting Relationships and Endospan Option” below.

Identifiable Intangible Assets

The following table presents details of the identifiable intangible assets recognized in connection with the Endospan Acquisition (in thousands, except estimated useful life):


Identifiable Intangible Assets	Fair Value		Estimated Useful Life (Years)
Developed technology	$	31,300	10.0
Trade name	1,600		15.0
In-process research and development (“IPR&D”)	38,900		Indefinite
Total identifiable intangible assets	$	71,800

The weighted-average amortization period for the acquired amortizable intangible assets was approximately 10.2 years. The IPR&D asset is considered indefinite-lived and is not amortized until the underlying project is completed or abandoned.

Fair Value Measurements

The acquisition-date fair values of the identifiable intangible assets were estimated using income-based valuation techniques. Significant assumptions included forecasted revenues and operating results, expected commercialization and regulatory timelines, estimated useful lives, and discount rates. The acquisition-date fair value of the contingent consideration was estimated using a Monte Carlo simulation based primarily on forecasted NEXUS™ revenues, revenue volatility, discount rates, credit risk, and the expected timing of payment.

These fair value measurements were based on significant unobservable inputs and were classified as Level 3 measurements. See Note 5 – “Financial Instruments” for additional information regarding the subsequent measurement of contingent consideration.

Settlement of Preexisting Relationships and Endospan Option

Artivion and Endospan entered into a loan agreement (the “Endospan Loan”), dated September 11, 2019, by which Artivion funded Endospan a secured loan of $15.0 million and also an amendment to the Endospan Loan, dated July 1, 2024, by which we funded Endospan additional secured loans of $25.0 million (“Additional Endospan Loan”) and together with the Endospan Loan, the (“Endospan Loans”). We elected the fair value option for recording the Endospan Loans. Immediately before the effective settlement of the Endospan Loans, we recognized a settlement gain of $4.3 million in Other income in the Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income to adjust the Endospan Loans to their acquisition-date fair value and included the $24.7 million fair value of the Endospan Loans as part of the fair value of the total consideration transferred.

Before the Endospan Acquisition, we had prepaid $3.0 million in advance deposits relating to certain purchase orders with Endospan. In connection with the settlement of this preexisting contractual relationship, the fair value of the settled relationship, which approximated its carrying amount, was included as part of the fair value of the total consideration transferred, and no settlement gain or loss was recognized.

In connection with the Agreement, we had recognized the value of the option right (“Endospan Option”) of $3.1 million, which was reflected in Other current assets in the Condensed Consolidated Balance Sheets. In connection with the exercise of the option to effect the Endospan Acquisition, the carrying amount of the Endospan Option was included as part of the fair value of the total consideration transferred, and no gain or loss was recognized.

Accordingly, the amounts associated with the Endospan Loans, advance deposits, and Endospan Option were included in the calculation of consideration transferred but were not recognized as acquired assets because they represented the settlement or exercise of preexisting contractual relationships accounted for separately from the business combination.

Sale of PerClot	6 Months Ended
Sale of PerClot	Jun. 30, 2026
Discontinued Operations and Disposal Groups [Abstract]
Sale of PerClot	Sale of PerClot Overview On July 28, 2021 we entered into an asset purchase agreement, Transitional Manufacturing and Supply Agreement (“TMSA”), and other ancillary agreements related to the sale of PerClot®, a polysaccharide hemostatic agent used in surgery (“PerClot”), to a subsidiary of Baxter International, Inc. (“Baxter”) and an agreement to terminate all of our material agreements with Starch Medical, Inc. (“SMI”) related to PerClot (collectively the “Baxter Transaction”). Under the terms of the Baxter Transaction, Baxter will pay an aggregate of up to $54.5 million in consideration (we will receive up to $41.0 million and SMI will receive up to $13.5 million), consisting of (i) $25.0 million at closing, of which $6.0 million was paid to SMI; (ii) $18.8 million upon our receipt of Premarket Approval (“PMA”) from the US Food and Drug Administration (the “FDA”) for PerClot and our transfer of the PMA to Baxter, of which $4.5 million was paid to SMI; and (iii) up to $10.0 million upon Baxter’s achievement of certain cumulative worldwide net sales of PerClot prior to December 31, 2026 and December 31, 2027, of which up to $3.0 million is payable to SMI. In addition, at the conclusion of our manufacturing and supply services for Baxter, Baxter will pay $0.8 million upon transfer of our PerClot manufacturing equipment. Under the terms of the Baxter Transaction, we will continue to provide to Baxter certain transition services relating to the sale of SMI PerClot outside of the US. Within the terms of the TMSA, we will manufacture and supply PerClot for Baxter post PMA for a contractual period. The TMSA has been extended for an additional 24-month term and will expire in February 2027. PerClot PMA Upon receipt of the PMA in May 2023, under the terms of the TMSA, we began manufacturing and supplying PerClot for Baxter and recorded $1.9 million and $2.4 million of PerClot revenues on the Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income during the three and six months ended June 30, 2026, respectively, as compared to $1.0 million and $1.8 million during the three and six months ended June 30, 2025, respectively. PerClot Sales Milestone During the second half of 2025, upon Baxter’s achievement of certain cumulative worldwide net sales of PerClot, we recorded a pre-tax gain of $7.0 million included as Gain from sale of non-financial assets within the Consolidated Statements of Operations and Comprehensive Income (Loss) for the year ended December 31, 2025. The gain is comprised of a cash payment of $5.0 million from Baxter, a receivable of $5.0 million due from Baxter, and a payable of $3.0 million due to SMI. The receivable and payable are reflected in Other receivables and Other current liabilities, respectively, in the Consolidated Balance Sheets as of December 31, 2025. Pursuant to the terms of the Baxter Transaction, we made a payment of $1.5 million to SMI in January 2026 in connection with Baxter’s achievement of the PerClot sales milestone. As of June 30, 2026, $1.5 million remained payable to SMI and $5.0 million was receivable from Baxter, which were reflected in Other current liabilities and Other receivables, respectively, in the Condensed Consolidated Balance Sheets.

Goodwill and Other Intangible Assets (Schedule of Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Intangible Asset, Goodwill and Other [Abstract]
Amortization expense	$ 4,226	$ 3,427	$ 8,137	$ 6,815

Income Taxes	6 Months Ended
Income Taxes	Jun. 30, 2026
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income Tax Expense Our effective income tax rate was (15)% and (6)% for the three and six months ended June 30, 2026, respectively, as compared to 61% and 29% for the three and six months ended June 30, 2025, respectively. Our income tax rate in each period varied from the US statutory rate of 21% predominately due to state income taxes, non-deductible executive compensation, changes in our valuation allowance for current period losses and changes in estimates of our expected recovery of net deferred tax assets, excess tax deductions on stock-based compensation, and foreign withholding taxes. The year-over-year changes to the effective income tax rate were largely attributable to the shift from pre-tax book income in each respective period in 2025 to pre-tax book losses in each respective period in 2026. On July 4, 2025 the One Big Beautiful Bill Act (“OBBBA”) was enacted in the US. The OBBBA includes significant provisions, such as the permanent extension of certain expiring provisions of the Tax Cuts and Jobs Act, modifications to the international tax framework, and the restoration of favorable tax treatment for certain business provisions. The legislation has multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. We have reflected the impact of the enactment in our results for the three and six months ended June 30, 2026. Subsequent to June 30, 2026, in connection with the ongoing examination of the Company’s 2022 German income tax return, the Company received initial correspondence from the German Federal Central Tax Office regarding the Company’s tax treatment of certain transactions related to its intercompany financing arrangements. The examination remains in its preliminary stages, and no assessment has been issued. The Company has evaluated the information received from the tax authority, including the positions asserted in the correspondence, and continues to believe that its tax treatment is supportable and meets the more-likely-than-not recognition threshold under ASC 740, Income Taxes. Accordingly, no adjustment has been recorded in the accompanying consolidated financial statements. While the ultimate outcome of the matter is uncertain and cannot be predicted with certainty at this time, if the tax authority were to prevail in full, the additional tax exposure associated with the matter would be approximately €7 million, excluding any related interest and penalties.

Inventories and Deferred Preservation Costs (Narrative) (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Inventory [Line Items]
Consignment inventory	$ 16,900	$ 14,900
Deferred preservation costs	$ 53,365	$ 54,531
Domestic
Inventory [Line Items]
Consignment inventory percentage	35.00%	33.00%
International
Inventory [Line Items]
Consignment inventory percentage	65.00%	67.00%

Acquisition of Ascyrus (Details) $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended
Acquisition of Ascyrus (Details) $ in Thousands	Sep. 02, 2020 USD ($)	Jul. 31, 2026 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($)
Business Combination [Line Items]
Current portion of contingent consideration			$ 25,000		$ 25,000		$ 20,690
Change in fair value of contingent consideration					9,710	$ (210)
Ascyrus Medical LLC
Business Combination [Line Items]
Equity ownership percent	100.00%
Cash consideration	$ 60,000
Common stock value issued in business combination	20,000
Business combination, contingent consideration, liability			70,300		70,300		$ 60,600
Current portion of contingent consideration			25,000		25,000
Change in fair value of contingent consideration			$ 8,000	$ 2,600	$ 9,700	$ (200)
Ascyrus Medical LLC \| Subsequent Event
Business Combination [Line Items]
Payment for contingent consideration liability, financing activities		$ 25,000
Ascyrus Medical LLC \| Measurement Input, Discount Rate
Business Combination [Line Items]
Contingent consideration, measurement input			0.16		0.16
Ascyrus Medical LLC \| FDA Approval IDE for AMDS
Business Combination [Line Items]
Cash consideration	10,000
Common stock value issued in business combination	10,000
Ascyrus Medical LLC \| FDA Approval PMA for AMDS
Business Combination [Line Items]
Cash consideration	25,000
Ascyrus Medical LLC \| AMDS Obtained In Japan
Business Combination [Line Items]
Cash consideration	10,000
Ascyrus Medical LLC \| AMDS Obtained In China
Business Combination [Line Items]
Cash consideration	10,000
Ascyrus Medical LLC \| Additional Potential Cash Payment If Japan Or China Obtains Approval
Business Combination [Line Items]
Cash consideration	$ 55,000
Ascyrus Medical LLC \| Following FDA Approval For AMDS
Business Combination [Line Items]
Aggregate amount of consideration transferred					$ 100,000
Period of required contingent consideration	3 years
Ascyrus Medical LLC \| Maximum
Business Combination [Line Items]
Aggregate amount of consideration transferred	$ 200,000
Ascyrus Medical LLC \| Maximum \| Additional Potential Cash Payment If Japan Or China Obtains Approval
Business Combination [Line Items]
Cash consideration	75,000
Ascyrus Medical LLC \| Minimum \| Additional Potential Cash Payment If Japan Or China Obtains Approval
Business Combination [Line Items]
Cash consideration	$ 65,000

Financial Instruments (Narrative) (Details) - USD ($)		3 Months Ended		6 Months Ended
Financial Instruments (Narrative) (Details) - USD ($)	May 18, 2026	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Realized investment gains (losses)		$ 0	$ 0	$ 0	$ 0
Endospan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 26,227,000
Endospan \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 26,200,000

Acquisition of Endospan (Purchase Price Allocation) (Details) - USD ($) $ in Thousands	May 18, 2026	Jun. 30, 2026	Dec. 31, 2025
Purchase Price Allocation
Goodwill		$ 349,862	$ 254,091
Endospan
Business Combination, Consideration Transferred [Abstract]
Cash consideration	$ 121,000
Noncash settlement of preexisting relationships and Endospan Option	30,811
Contingent consideration	26,227
Fair value of total consideration transferred	178,062
Purchase Price Allocation
Cash and cash equivalents	4,363
Intangible assets, net	71,800
Net other assets/liabilities acquired	2,693
Goodwill	99,206
Net assets acquired	178,062
Endospan \| Endospan Loans
Business Combination, Consideration Transferred [Abstract]
Noncash settlement of preexisting relationships and Endospan Option	24,700
Endospan \| Buyer Deposits
Business Combination, Consideration Transferred [Abstract]
Noncash settlement of preexisting relationships and Endospan Option	3,000
Endospan \| Endospan Option
Business Combination, Consideration Transferred [Abstract]
Noncash settlement of preexisting relationships and Endospan Option	3,100
Endospan \| Cash Consideration
Business Combination, Consideration Transferred [Abstract]
Cash consideration	106,818
Endospan \| To Settle Endospan Debt Obligations
Business Combination, Consideration Transferred [Abstract]
Cash consideration	$ 14,206

Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2026 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 254,091
Endospan acquisition	99,206
Foreign currency translation	(3,435)
Ending balance	$ 349,862

Financial Instruments (Schedule of Financial Instruments Measured at Fair Value) (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	$ 37,023	$ 41,677
Current portion of contingent consideration	25,000	20,690
Non-current contingent consideration	71,517	39,890
Total liabilities	96,517	60,580
Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	37,023	21,805
Current portion of contingent consideration	0	0
Non-current contingent consideration	0	0
Total liabilities	0	0
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	0	0
Current portion of contingent consideration	0	0
Non-current contingent consideration	0	0
Total liabilities	0	0
Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total assets	0	19,872
Current portion of contingent consideration	25,000	20,690
Non-current contingent consideration	71,517	39,890
Total liabilities	96,517	60,580
Money market funds
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	36,351	20,725
Money market funds \| Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	36,351	20,725
Money market funds \| Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	0	0
Money market funds \| Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	0	0
Certificates of deposit
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	672	1,080
Certificates of deposit \| Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	672	1,080
Certificates of deposit \| Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	0	0
Certificates of deposit \| Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Cash equivalents	$ 0	0
Endospan Loans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Endospan Loans		19,872
Endospan Loans \| Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Endospan Loans		0
Endospan Loans \| Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Endospan Loans		0
Endospan Loans \| Level 3
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Endospan Loans		$ 19,872

Debt (Schedule of Short-Term and Long-Term Balances of Term Loan) (Details) - USD ($) $ in Thousands	Jun. 30, 2026	May 31, 2026	Dec. 31, 2025
Debt Instrument [Line Items]
Total principal debt	$ 370,000		$ 220,000
Less: Unamortized debt issuance costs	(6,577)		(4,886)
Total debt	363,423		215,114
Less: Current portion of long-term debt	0		0
Long-term debt, net	363,423		215,114
New Delayed Draw Term Loan Facility
Debt Instrument [Line Items]
Unamortized debt issuance costs			1,100
Secured Debt \| Term Loan Facility
Debt Instrument [Line Items]
Total principal debt	190,000		190,000
Less: Unamortized debt issuance costs	(500)
Secured Debt \| New Delayed Draw Term Loan Facility
Debt Instrument [Line Items]
Total principal debt	150,000		0
Less: Unamortized debt issuance costs	(1,100)	$ (1,100)
Revolving Credit Facility
Debt Instrument [Line Items]
Unamortized debt issuance costs	1,400		1,500
Revolving Credit Facility \| Revolving Credit Facility
Debt Instrument [Line Items]
Total principal debt	30,000		$ 30,000
Less: Unamortized debt issuance costs	$ (200)

Goodwill and Other Intangible Assets (Schedule of Carrying Values of Indefinite Lived Intangible Assets) (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Indefinite-lived Intangible Assets [Line Items]
Goodwill	$ 349,862	$ 254,091
In-process R&D
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	41,121	2,291
Procurement contracts and agreements
Indefinite-lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	$ 2,013	$ 2,013

Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
Revenue Recognition (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Disaggregation of Revenue [Line Items]
Total revenues	$ 125,757	$ 112,972	$ 242,094	$ 211,950
North America
Disaggregation of Revenue [Line Items]
Total revenues	62,333	57,569	121,028	105,362
EMEA
Disaggregation of Revenue [Line Items]
Total revenues	44,548	38,713	88,534	75,758
APAC
Disaggregation of Revenue [Line Items]
Total revenues	12,169	11,131	20,859	19,345
LATAM
Disaggregation of Revenue [Line Items]
Total revenues	$ 6,707	$ 5,559	$ 11,673	$ 11,485

Commitments and Contingencies	6 Months Ended
Commitments and Contingencies	Jun. 30, 2026
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Liability Claims In the normal course of business, we are made aware of adverse events involving our products and tissues. Future adverse events could ultimately give rise to a lawsuit against us, and liability claims may be asserted against us in the future based on past events that we are not aware of at the present time. We maintain claims-made insurance policies to mitigate our financial exposure to product and tissue processing liability claims. Claims-made insurance policies generally cover only those asserted claims and incidents that are reported to the insurance carrier while the policy is in effect. The amounts recorded in these Condensed Consolidated Financial Statements as of June 30, 2026 and December 31, 2025 represent our estimate of the probable losses and anticipated recoveries for incurred but not reported claims related to products sold and services performed prior to the balance sheet date.

Cover Page - shares	6 Months Ended
Cover Page - shares	Jun. 30, 2026	Jul. 31, 2026
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2026
Document Transition Report	false
Entity File Number	1-13165
Entity Registrant Name	ARTIVION, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	59-2417093
Entity Address, Address Line One	1655 Roberts Boulevard, NW
Entity Address, City or Town	Kennesaw
Entity Address, State or Province	GA
Entity Address, Postal Zip Code	30144
City Area Code	770
Local Phone Number	419-3355
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	AORT
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		48,756,221
Entity Central Index Key	0000784199
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2026
Document Fiscal Period Focus	Q2
Amendment Flag	false

Income Taxes (Details) - EUR (€) € in Millions	3 Months Ended		6 Months Ended
Income Taxes (Details) - EUR (€) € in Millions	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Tax Disclosure [Abstract]
Effective income tax rate expense	(15.00%)	61.00%	(6.00%)	29.00%
Potential additional tax exposure	€ 7		€ 7

Debt (Narrative) (Details)						1 Months Ended	3 Months Ended		6 Months Ended
Debt (Narrative) (Details)	Sep. 12, 2025 USD ($)	Jul. 01, 2025 USD ($) shares	May 28, 2025 USD ($) shares	Jan. 18, 2024 USD ($)	Jun. 18, 2020 USD ($) $ / shares	May 31, 2026 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Dec. 31, 2025 USD ($)
Line of Credit Facility [Line Items]
Proceeds from issuance of long-term debt, net									$ 148,875,000	$ 0
Debt issuance costs, net							$ 6,577,000		6,577,000		$ 4,886,000
Long-term debt							363,423,000		363,423,000		$ 215,114,000
Credit Facilities
Line of Credit Facility [Line Items]
Non-cash amortization of debt issuance costs							400,000		700,000
Credit Facilities, Convertible Senior Notes and Old Credit Facilities
Line of Credit Facility [Line Items]
Non-cash amortization of debt issuance costs								$ 500,000		1,000,000.0
Convertible Debt
Line of Credit Facility [Line Items]
Debt instrument, face amount					$ 100,000,000.0
Interest rate on amounts borrowed					4.25%
Proceeds from issuance of convertible debt					$ 96,500,000
Conversion price (in dollars per share) \| $ / shares					$ 23.46
Interest expense							0	$ 800,000	0	$ 2,100,000
Conversion ratio					0.0426203
New Delayed Draw Term Loan Facility \| Secured Debt
Line of Credit Facility [Line Items]
Debt instrument, face amount	$ 150,000,000.0
Exchange Agreements \| Convertible Debt
Line of Credit Facility [Line Items]
Cash payment			$ 99,500,000
Exchange aggregate shares (In shares) \| shares		19,605	4,334,347
Cash payment amount			$ 1,700,000
Long-term debt		$ 500,000
Revolving Credit Facility \| Senior Secured, Interest-Only, Credit Facilities
Line of Credit Facility [Line Items]
Debt instrument, face amount				$ 350,000,000.0
Revolving Credit Facility \| Revolving Credit Facility
Line of Credit Facility [Line Items]
Credit facility aggregate commitments				60,000,000.0
Proceeds from issuance of long-term debt, net				30,000,000.0
Debt instrument, unused borrowing capacity, amount				$ 30,000,000.0			$ 30,000,000.0		$ 30,000,000.0
Line of credit facility, unused capacity, commitment fee percentage	0.50%
Interest rate on amounts borrowed							7.19%		7.19%
Debt issuance costs, net							$ 200,000		$ 200,000
Revolving Credit Facility \| Revolving Credit Facility \| Base Rate
Line of Credit Facility [Line Items]
Credit facility margin	2.50%
Revolving Credit Facility \| Revolving Credit Facility \| SOFR
Line of Credit Facility [Line Items]
Credit facility margin	3.50%
Revolving Credit Facility \| Revolving Credit Facility \| If Prepayment Occurs Prior to July 18, 2027
Line of Credit Facility [Line Items]
Debt prepayment premium				1.00%
Secured Debt \| For Period from Second Quarter To Fourth Quarter of Fiscal Year 2024
Line of Credit Facility [Line Items]
Debt Instrument, net leverage ratio				6.25
Secured Debt \| From First Quarter of Fiscal Year 2025 and Thereafter
Line of Credit Facility [Line Items]
Debt Instrument, net leverage ratio				5.75
Secured Debt \| Term Loan Facility
Line of Credit Facility [Line Items]
Debt instrument, face amount				$ 190,000,000.0
Proceeds from issuance of long-term debt, net				190,000,000.0
Interest rate on amounts borrowed							8.44%		8.44%
Effective interest rate							9.07%		9.07%
Debt issuance costs, net							$ 500,000		$ 500,000
Secured Debt \| Delayed Draw Term Loan Facility
Line of Credit Facility [Line Items]
Debt instrument, face amount				$ 100,000,000.0
Secured Debt \| Term Loan Facility and Revolving Credit Facility
Line of Credit Facility [Line Items]
Debt instrument, extension period	1 year
Secured Debt \| New Delayed Draw Term Loan Facility
Line of Credit Facility [Line Items]
Proceeds from issuance of debt						$ 150,000,000.0
Unused borrowing capacity, fee percentage	1.00%
Interest rate on amounts borrowed							8.40%		8.40%
Effective interest rate							8.79%		8.79%
Debt issuance costs, net						1,100,000	$ 1,100,000		$ 1,100,000
Payments of debt issuance costs						1,100,000
Proceeds from issuance of debt, net						148,900,000
Amortized to interest expense						$ 2,300,000
Secured Debt \| New Delayed Draw Term Loan Facility \| Base Rate
Line of Credit Facility [Line Items]
Credit facility margin	3.75%
Secured Debt \| New Delayed Draw Term Loan Facility \| SOFR
Line of Credit Facility [Line Items]
Credit facility margin	4.75%

Inventories and Deferred Preservation Costs (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 40,643	$ 36,355
Work-in-process	21,399	17,133
Finished goods	41,322	38,939
Inventories	$ 103,364	$ 92,427

Stock Compensation (Details) - USD ($) $ in Millions	6 Months Ended
Stock Compensation (Details) - USD ($) $ in Millions	Jun. 30, 2026	Jun. 30, 2025
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
ESPP, percentage of market price for eligible employees	85.00%
Employee stock purchase plan (in shares)	41,000	44,000
RSAs, RSUs And PSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized awards from approved stock incentive plans (in shares)	839,000	897,000
Aggregate grant date market value	$ 28.6	$ 23.2
Stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Authorized awards from approved stock incentive plans (in shares)	0	0

(Loss) Income Per Common Share - Narrative (Details) - shares shares in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2025
Stock Options And Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)	178	150

Segment Information (Narrative) (Details)	3 Months Ended		6 Months Ended
Segment Information (Narrative) (Details)	Jun. 30, 2026 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2026 USD ($) segment	Jun. 30, 2025 USD ($)
Segment Reporting [Line Items]
Number of reportable segments \| segment			2
Total revenues	$ 125,757,000	$ 112,972,000	$ 242,094,000	$ 211,950,000
Intersegment Eliminations
Segment Reporting [Line Items]
Total revenues			$ 0

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2026	Dec. 31, 2025
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	50,179,000	49,330,000
Treasury stock at cost, shares (in shares)	1,487,000	1,487,000

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting	The accompanying Condensed Consolidated Financial Statements include the accounts of Artivion, Inc. and its subsidiaries (“Artivion,” the “Company,” “we,” or “us”). All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying Consolidated Balance Sheet as of December 31, 2025 has been derived from audited financial statements. The accompanying unaudited Condensed Consolidated Financial Statements as of, and for the three and six months ended, June 30, 2026 and 2025 have been prepared in accordance with (i) accounting principles generally accepted in the United States of America (“US GAAP”) for interim financial information and (ii) the instructions to Form 10-Q and Rule 10-01 of Regulation S-X of the US Securities and Exchange Commission (the “SEC”). Accordingly, such statements do not include all the information and disclosures that are required by US GAAP for a complete presentation of financial statements. In the opinion of management, all adjustments (including those of a normal, recurring nature) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 30, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026. These Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and Notes included in Artivion’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on February 18, 2026.
Foreign Currency Translation and Transactions	Foreign Currency Translation and Transactions Assets and liabilities of international subsidiaries whose functional currency is the local currency are translated at the rate of exchange in effect on the balance sheet date; income and expenses are translated at the average exchange rates throughout the year. Foreign currency exchange rate realized and unrealized gains and losses resulting from transactions are included in Other expense (income), net in our Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income and resulted in a net loss of $0.7 million and $1.6 million for the three and six months ended June 30, 2026, respectively, as compared to a net gain of $4.5 million and $7.4 million for the three and six months ended June 30, 2025, respectively. Currency translation adjustments resulting from intra-entity loans that are of a long-term investment nature, net of tax, are included in Accumulated other comprehensive loss and resulted in a net loss of $0.5 million and $7.9 million for the three and six months ended June 30, 2026, respectively, as compared to a net gain of $9.8 million and $13.6 million for the three and six months ended June 30, 2025, respectively.
Business Combinations	Business Combinations We account for business combinations using the acquisition method. The identifiable assets acquired and liabilities assumed are recognized at their respective acquisition-date fair values. The excess of the consideration transferred over the estimated fair value of the identifiable net assets acquired is recorded as goodwill. Acquisition-related costs are expensed as incurred and recognized within general, administrative, and marketing in the Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income.
New Accounting Pronouncements and Not Yet Effective	New Accounting Pronouncements Recently Adopted In July 2025 the FASB issued ASU No. 2025-05 – Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets, which provides a practical expedient for estimating expected credit losses on current accounts receivable and current contract assets arising from transactions accounted for under Topic 606 – Revenue from Contracts with Customers. Under this practical expedient, entities may assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. The updated standard is effective for financial statements issued for fiscal years beginning after December 15, 2025. We adopted ASU 2025-05 on a prospective basis effective January 1, 2026. The adoption of ASU 2025-05 did not have a material impact on our financial condition or results of operations and did not affect any amounts previously reported for the three months ended March 31, 2026. In September 2025 the FASB issued ASU No. 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, which modernizes the accounting for internal-use software costs under Subtopic 350-40. The amendments remove references to prescriptive and sequential software development stages and clarify when entities begin capitalizing internal-use software costs. The updated standard is effective for financial statements issued for fiscal years beginning after December 15, 2027. During the second quarter of 2026, we adopted ASU 2025-06 on a prospective basis effective January 1, 2026. See further discussion below regarding our accounting for internal-use software. Not Yet Effective In November 2024 the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses to improve the disclosures about a public business entity’s expenses for more detailed information about the types of expenses in commonly presented expense captions such as cost of sales; selling, general, and administrative expenses; and research and development. The updated accounting guidance, among other things, requires quantitative disclosures for employee compensation, selling expenses, and purchases of inventory. The updated guidance is effective for financial statements issued for fiscal years beginning after December 15, 2026. We are currently evaluating the impacts of the new standard.
Internal-Use Software, net	Internal-Use Software, net Following the adoption of ASU 2025-06, we capitalize eligible costs incurred to develop or obtain internal-use software when management has authorized and committed to funding the software project and it is probable that the project will be completed and the software will be used to perform its intended function. Costs incurred before these criteria are met, as well as training, maintenance, data conversion and other costs that do not qualify for capitalization, are expensed as incurred. Capitalized internal-use software includes software used in manufacturing operations, which is included in Property and equipment, net, and software used in non-manufacturing activities, which is included in Other intangible assets, net, in the Condensed Consolidated Balance Sheets. We apply the disclosure requirements of ASC 360-10 to all capitalized internal-use software, regardless of balance sheet presentation. Capitalized internal-use software is stated at cost less accumulated amortization. Capitalized internal-use software is amortized on a straight-line basis over the estimated useful lives of the related assets, generally five years, beginning when the software is substantially complete and ready for its intended use.

Acquisition of Endospan (Schedule Identifiable Intangible Assets Recognized) (Details) - Endospan $ in Thousands	May 18, 2026 USD ($)
Business Combination [Line Items]
Intangible assets, net	$ 71,800
In-process R&D
Business Combination [Line Items]
In-process research and development (“IPR&D”)	38,900
Developed technology
Business Combination [Line Items]
Identifiable intangible assets	$ 31,300
Weighted Average Useful Life (Years)	10 years
Trade name
Business Combination [Line Items]
Identifiable intangible assets	$ 1,600
Weighted Average Useful Life (Years)	15 years

Sale of PerClot (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
Sale of PerClot (Details) - USD ($) $ in Thousands	Jul. 28, 2021	Jan. 31, 2026	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025
Disposal Group, Including Discontinued Operations [Line Items]
Total revenues			$ 125,757	$ 112,972	$ 242,094	$ 211,950
Per Clot
Disposal Group, Including Discontinued Operations [Line Items]
Consideration for sale of assets	$ 41,000						$ 5,000
Total revenues			1,900	$ 1,000	2,400	$ 1,800
Gain from sale of non-financial assets							7,000
Notes and loans receivable			5,000		5,000		5,000
Per Clot \| Transfer Of Perclot Manufacturing Equipment
Disposal Group, Including Discontinued Operations [Line Items]
Contingent consideration receivable	800
Per Clot \| Upon Our Receipt of Premarket Approval
Disposal Group, Including Discontinued Operations [Line Items]
Proceeds from sale of assets	18,800
Per Clot \| Starch Medical Inc.
Disposal Group, Including Discontinued Operations [Line Items]
Contingent liability payment	4,500	$ 1,500
Payable			$ 1,500		$ 1,500		$ 3,000
Per Clot \| Artivion Inc. And Starch Medical Inc.
Disposal Group, Including Discontinued Operations [Line Items]
Consideration for sale of assets	54,500
Proceeds from sale of assets	25,000
Per Clot \| Artivion Inc. And Starch Medical Inc. \| Baxter Achievement Of Worldwide Sales
Disposal Group, Including Discontinued Operations [Line Items]
Contingent consideration receivable	$ 10,000
Contractual period	24 months
Per Clot \| Starch Medical Inc.
Disposal Group, Including Discontinued Operations [Line Items]
Consideration for sale of assets	$ 13,500
Contingent liability payment	6,000
Per Clot \| Starch Medical Inc. \| Baxter Achievement Of Worldwide Sales
Disposal Group, Including Discontinued Operations [Line Items]
Contingent liability payment	$ 3,000

Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Deficit	Accumulated Other Comprehensive Loss	Treasury Stock
Beginning balance (in shares) at Dec. 31, 2024		43,432
Beginning balance at Dec. 31, 2024	$ 276,200	$ 434	$ 376,607	$ (61,266)	$ (24,927)	$ (14,648)
Beginning balance, treasury stock (in shares) at Dec. 31, 2024						(1,487)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	840			840
Other comprehensive income (loss), net of tax	22,099				22,099
Settlement of convertible senior notes (in shares)		4,334
Settlement of convertible senior notes	102,137	$ 44	102,093
Equity compensation (in shares)		600
Equity compensation	14,167	$ 6	14,161
Exercise of options (in shares)		182
Exercise of options	3,498	$ 2	3,496
Employee stock purchase plan (in shares)		44
Employee stock purchase plan	961		961
Ending balance (in shares) at Jun. 30, 2025		48,592
Ending balance at Jun. 30, 2025	419,902	$ 486	497,318	(60,426)	(2,828)	$ (14,648)
Ending balance, treasury stock (in shares) at Jun. 30, 2025						(1,487)
Beginning balance (in shares) at Mar. 31, 2025		44,190
Beginning balance at Mar. 31, 2025	294,252	$ 442	388,825	(61,771)	(18,596)	$ (14,648)
Beginning balance, treasury stock (in shares) at Mar. 31, 2025						(1,487)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	1,345			1,345
Other comprehensive income (loss), net of tax	15,768				15,768
Settlement of convertible senior notes (in shares)		4,334
Settlement of convertible senior notes	102,137	$ 44	102,093
Equity compensation (in shares)		57
Equity compensation	6,122		6,122
Exercise of options (in shares)		11
Exercise of options	278		278
Ending balance (in shares) at Jun. 30, 2025		48,592
Ending balance at Jun. 30, 2025	419,902	$ 486	497,318	(60,426)	(2,828)	$ (14,648)
Ending balance, treasury stock (in shares) at Jun. 30, 2025						(1,487)
Beginning balance (in shares) at Dec. 31, 2025		49,330
Beginning balance at Dec. 31, 2025	$ 448,232	$ 493	516,604	(51,498)	(2,719)	$ (14,648)
Beginning balance, treasury stock (in shares) at Dec. 31, 2025	(1,487)					(1,487)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	$ (12,093)			(12,093)
Other comprehensive income (loss), net of tax	(9,757)				(9,757)
Equity compensation (in shares)		709
Equity compensation	16,578	$ 7	16,571
Exercise of options (in shares)		99
Exercise of options	1,553	$ 1	1,552
Employee stock purchase plan (in shares)		41
Employee stock purchase plan	1,072	$ 1	1,071
Ending balance (in shares) at Jun. 30, 2026		50,179
Ending balance at Jun. 30, 2026	$ 445,585	$ 502	535,798	(63,591)	(12,476)	$ (14,648)
Ending balance, treasury stock (in shares) at Jun. 30, 2026	(1,487)					(1,487)
Beginning balance (in shares) at Mar. 31, 2026		49,983
Beginning balance at Mar. 31, 2026	$ 450,467	$ 500	526,261	(50,081)	(11,565)	$ (14,648)
Beginning balance, treasury stock (in shares) at Mar. 31, 2026						(1,487)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(13,510)			(13,510)
Other comprehensive income (loss), net of tax	(911)				(911)
Equity compensation (in shares)		106
Equity compensation	8,164	$ 1	8,163
Exercise of options (in shares)		90
Exercise of options	1,375	$ 1	1,374
Ending balance (in shares) at Jun. 30, 2026		50,179
Ending balance at Jun. 30, 2026	$ 445,585	$ 502	$ 535,798	$ (63,591)	$ (12,476)	$ (14,648)
Ending balance, treasury stock (in shares) at Jun. 30, 2026	(1,487)					(1,487)

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 77,316	$ 64,908
Trade receivables, net	97,928	89,758
Other receivables	12,835	13,921
Inventories	103,364	92,427
Deferred preservation costs	53,365	54,531
Prepaid expenses and other	26,572	42,537
Total current assets	371,380	358,082
Goodwill	349,862	254,091
Acquired technology, net	149,274	123,664
Operating lease right-of-use assets, net	36,580	34,701
Property and equipment, net	73,699	64,988
Other intangibles, net	74,696	32,831
Deferred tax assets, net	1,216	1,201
Other long-term assets	15,227	15,238
Total assets	1,071,934	884,796
Current liabilities:
Accounts payable	20,870	16,042
Accrued compensation	17,843	22,484
Accrued expenses	16,252	16,447
Accrued interest	6,526	4,815
Taxes payable	5,580	7,489
Accrued procurement fees	1,541	3,436
Current portion of contingent consideration	25,000	20,690
Current maturities of operating leases	5,058	4,649
Current portion of finance lease obligations	860	726
Other current liabilities	7,401	4,778
Total current liabilities	106,931	101,556
Long-term debt, net	363,423	215,114
Non-current contingent consideration	71,517	39,890
Non-current maturities of operating leases	35,824	34,427
Deferred tax liabilities, net	25,884	24,308
Deferred compensation liability	10,739	9,464
Non-current finance lease obligations	2,802	2,698
Other long-term liabilities	9,229	9,107
Total liabilities	626,349	436,564
Commitments and contingencies
Stockholders’ equity:
Preferred stock $0.01 par value per share, 5,000 shares authorized, no shares issued	0	0
Common stock $0.01 par value per share, 75,000 shares authorized, 50,179 and 49,330 shares issued as of June 30, 2026 and December 31, 2025, respectively	502	493
Additional paid-in capital	535,798	516,604
Retained deficit	(63,591)	(51,498)
Accumulated other comprehensive loss	(12,476)	(2,719)
Treasury stock, at cost, 1,487 shares as of June 30, 2026 ‎and December 31, 2025	(14,648)	(14,648)
Total stockholders’ equity	445,585	448,232
Total liabilities and stockholders’ equity	$ 1,071,934	$ 884,796

Stock Compensation	6 Months Ended
Stock Compensation	Jun. 30, 2026
Share-Based Payment Arrangement [Abstract]
Stock Compensation	Stock Compensation Overview We have stock option and stock incentive plans for employees and non-employee directors that provide for grants of restricted stock awards (“RSAs”), restricted stock units (“RSUs”), performance stock units (“PSUs”), and options to purchase shares of our common stock at exercise prices generally equal to the fair value of such stock at the dates of grant. We also maintain a stockholder-approved Employee Stock Purchase Plan (“ESPP”) for the benefit of our employees. The ESPP allows eligible employees to purchase common stock on a regular basis at the lower of 85% of the market price at the beginning or end of each offering period. Equity Grants During the six months ended June 30, 2026 the Compensation Committee of our Board of Directors (the “Committee”) authorized awards from approved stock incentive plans of RSAs to non-employee directors and RSUs and PSUs to certain employees and company officers, which, assuming that performance under the PSUs will be achieved at target levels, together totaled 839,000 shares and had an aggregate grant date fair value of $28.6 million. During the six months ended June 30, 2025 the Committee authorized awards from approved stock incentive plans of RSAs to non-employee directors and RSUs and PSUs to certain employees and company officers, which, assuming that performance under the PSUs were to be achieved at target levels, together totaled 897,000 shares and had an aggregate grant date fair value of $23.2 million. The Committee did not authorize any grants of stock options during the six months ended June 30, 2026 and 2025. Employees purchased common stock totaling 41,000 and 44,000 shares in the six months ended June 30, 2026 and 2025, respectively, through the ESPP.

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Net cash flows from operating activities:
Net (loss) income	$ (12,093)	$ 840
Adjustments to reconcile net (loss) income to net cash from operating activities:
Depreciation and amortization	13,088	10,984
Non-cash compensation	16,578	14,167
Non-cash lease expense	2,612	2,510
Write-down of inventories and deferred preservation costs	2,368	2,379
Deferred income taxes	(1,421)	(231)
Change in fair value of contingent consideration	9,710	(210)
Losses on inducement/extinguishment of debt	0	2,664
Other	(2,590)	(7,423)
Changes in operating assets and liabilities, net of acquisition:
Receivables	(7,971)	(9,660)
Inventories and deferred preservation costs	(10,752)	(5,521)
Prepaid expenses and other assets	(5,271)	(6,215)
Accounts payable, accrued expenses, and other liabilities	(4,370)	(6,226)
Net cash flows used in operating activities	(112)	(1,942)
Net cash flows from investing activities:
Capital expenditures	(18,751)	(6,925)
Acquisition of Endospan, net of cash acquired	(116,661)	0
Payments related to sale of non-financial assets	(1,500)	0
Other	(3,000)	0
Net cash flows used in investing activities	(139,912)	(6,925)
Net cash flows from financing activities:
Proceeds from issuance of long-term debt, net	148,875	0
Repayment of debt	0	(134)
Proceeds from exercise of stock options and issuance of common stock	2,625	4,459
Proceeds from financing insurance premiums	3,217	3,117
Principal payments on short-term notes payable	(1,440)	(554)
Other	(426)	(353)
Net cash flows provided by financing activities	152,851	6,535
Effect of exchange rate changes on cash and cash equivalents	(419)	2,345
Increase in cash and cash equivalents	12,408	13
Cash and cash equivalents beginning of period	64,908	53,463
Cash and cash equivalents end of period	$ 77,316	$ 53,476

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Jun. 30, 2026 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Anthony B. Semedo [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On June 10, 2026 Anthony B. Semedo, one of the Company’s directors, adopted Rule 10b5-1 trading arrangement, pursuant to which he may sell up to 10,000 shares of the Company’s common stock. The duration of the trading arrangement is from September 7, 2026 to June 30, 2027. This trading arrangement is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
Name	Anthony B. Semedo
Title	directors
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 10, 2026
Expiration Date	June 30, 2027
Arrangement Duration	296 days
Aggregate Available	10,000